Nanoform Finland (OSTO:NANOFS) Debt-to-Revenue : 3.91 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Nanoform Finland's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr11.79 Mil. Nanoform Finland's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr58.20 Mil. Nanoform Finland's annualized Revenue for the quarter that ended in Dec. 2023 was kr17.90 Mil. Nanoform Finland's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 3.91.

Nanoform Finland Debt-to-Revenue Historical Data

The historical data trend for Nanoform Finland's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland Debt-to-Revenue Chart

Nanoform Finland Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

74.69

10.00

3.92

1.99

2.44

Nanoform Finland Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															1.76	2.28	2.09	2.47	3.91

Competitive Comparison of Nanoform Finland's Debt-to-Revenue

For the Biotechnology subindustry, Nanoform Finland's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanoform Finland's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's Debt-to-Revenue falls into.

Nanoform Finland Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Nanoform Finland's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(11.79	+	58.201)	/	28.703
	=	2.44

Nanoform Finland's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(11.79	+	58.201)	/	17.896
	=	3.91

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Nanoform Finland Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanoform Finland (OSTO:NANOFS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OSTO:NANOFS) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

NANOFH:Finland 4YL:Germany

Address

Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790

Website

https://www.nanoform.com

Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OSTO:NANOFS) Headlines

No Headlines